Abstract

Background3-phosphoinositide-dependent protein kinase-1 (PDK1) acts as a master kinase of protein kinase A, G, and C family (AGC) kinase to predominantly govern cell survival, proliferation, and metabolic homeostasis. Although the regulations to PDK1 downstream substrates such as protein kinase B (AKT) and ribosomal protein S6 kinase beta (S6K) have been well established, the upstream regulators of PDK1, especially its degrader, has not been defined yet.MethodA clustered regularly interspaced short palindromic repeats (CRISPR)-based E3 ligase screening approach was employed to identify the E3 ubiquitin ligase for degrading PDK1. Western blotting, immunoprecipitation assays and immunofluorescence (IF) staining were performed to detect the interaction or location of PDK1 with speckle-type POZ protein (SPOP). Immunohistochemistry (IHC) staining was used to study the expression of PDK1 and SPOP in prostate cancer tissues. In vivo and in vitro ubiquitination assays were performed to measure the ubiquitination conjugation of PDK1 by SPOP. In vitro kinase assays and mass spectrometry approach were carried out to identify casein kinase 1 (CK1) and glycogen synthase kinase 3 (GSK3)-mediated PDK1 phosphorylation. The biological effects of PDK1 mutations and correlation with SPOP mutations were performed with colony formation, soft agar assays and in vivo xenograft mouse models.ResultsWe identified that PDK1 underwent SPOP-mediated ubiquitination and subsequent proteasome-dependent degradation. Specifically, SPOP directly bound PDK1 by the consensus degron in a CK1/GSK3β-mediated phosphorylation dependent manner. Pathologically, prostate cancer patients associated mutations of SPOP impaired PDK1 degradation and thus activated the AKT kinase, resulting in tumor malignancies. Meanwhile, mutations that occurred around or within the PDK1 degron, by either blocking SPOP to bind the degron or inhibiting CK1 or GSK3β-mediated PDK1 phosphorylation, could markedly evade SPOP-mediated PDK1 degradation, and played potently oncogenic roles via activating the AKT kinase.ConclusionsOur results not only reveal a physiological regulation of PDK1 by E3 ligase SPOP, but also highlight the oncogenic roles of loss-of-function mutations of SPOP or gain-of-function mutations of PDK1 in tumorigenesis through activating the AKT kinase.

Highlights

  • Phosphoinositide 3-kinases (PI3K)-Protein kinase B (AKT) signaling pathway plays crucial roles in modulating cell survival, proliferation and metabolic homeostasis, aberrations of which often result in metabolic disorders such as diabetes and cancers [1, 2]

  • We identified that 3-Phosphoinositide-dependent protein kinase-1 (PDK1) underwent speckletype POZ protein (SPOP)-mediated ubiquitination and subsequent proteasome-dependent degradation

  • Our results reveal a physiological regulation of PDK1 by E3 ligase SPOP, and highlight the oncogenic roles of loss-of-function mutations of SPOP or gain-of-function mutations of PDK1 in tumorigenesis through activating the AKT kinase

Read more

Summary

Introduction

Phosphoinositide 3-kinases (PI3K)-AKT signaling pathway plays crucial roles in modulating cell survival, proliferation and metabolic homeostasis, aberrations of which often result in metabolic disorders such as diabetes and cancers [1, 2]. Besides AKT, many other AGC family members including S6K, serum- and glucocorticoid-inducible protein kinase (SGK), polo-like kinase 1 (PLK), ribosomal S6 kinase (RSK) and protein kinase C (PKC), undergo PDK1-mediated phosphorylation and activation, contributing to diverse biological functions of PDK1 [7,8,9,10]. Accumulating evidence shows that the increased PDK1 protein abundance induced by the genomic amplification robustly contributes to its oncogenic functions in promoting tumorigenesis in different types of cancers [11,12,13]. Unraveling the upstream regulation of PDK1 protein turnover will likely provide insights for understanding PI3K-AKT roles in tumorigenesis, and potential targets for combating hyperactive-AKT-driven cancers

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.